Tight junction proteins in glial tumors development and progression
Frontiers in Cellular Neuroscience,
Год журнала:
2025,
Номер
19
Опубликована: Фев. 3, 2025
Tight
junctions
form
a
paracellular
barrier
in
epithelial
and
endothelial
cells,
they
regulate
the
diffusion
of
fluids,
molecules,
penetration
cells
across
tissue
compartments.
are
composed
group
integral
membrane
proteins,
which
include
claudin
family,
tight
junction-associated
Marvel
protein
junctional
adhesion
molecule
proteins
that
anchor
cytoskeleton,
such
as
zonula
occludens
cingulin
family.
Several
factors,
neurotransmitters
or
cytokines,
processes
like
ischemia/hypoxia,
inflammation,
tumorigenesis,
phosphorylation/dephosphorylation,
ubiquitination,
palmitoylation,
junction
proteins.
Claudins
involved
tumorigenesis
lead
to
glioma
formation.
In
gliomas,
there
is
noticeable
dysregulation
claudins,
occludin,
occludens-1
abundance,
their
dislocation
has
been
observed.
The
weakening
intercellular
cell
detachment
responsible
for
infiltration
into
surrounding
tissues.
Furthermore,
permeability
blood–brain
barrier,
formed
with
involvement
influences
development
peritumoral
edema
–
and,
simultaneously,
rate
drug
delivery
glial
tumor.
Understanding
environments
brain
tumors
crucial
predicting
tumor
progression
feasibility
chemotherapeutic
delivery.
This
knowledge
may
also
illuminate
differences
between
high
low-grade
gliomas.
Язык: Английский
The transformative potential of mRNA vaccines for glioblastoma and human cancer: technological advances and translation to clinical trials
Frontiers in Oncology,
Год журнала:
2024,
Номер
14
Опубликована: Сен. 27, 2024
Originally
devised
for
cancer
control,
mRNA
vaccines
have
risen
to
the
forefront
of
medicine
as
effective
instruments
control
infectious
disease,
notably
their
pivotal
role
in
combating
COVID-19
pandemic.
This
review
focuses
on
fundamental
aspects
development
vaccines,
e.g.,
tumor
antigens,
vector
design,
and
precise
delivery
methodologies,
–
highlighting
key
technological
advances.
The
recent,
promising
success
personalized
against
pancreatic
melanoma
illustrates
potential
value
other
intractable,
immunologically
resistant,
solid
tumors,
such
glioblastoma,
well
synergies
with
a
combinatorial,
immunotherapeutic
approach.
impact
progress
human
cancer,
including
head
neck
bladder
are
reviewed,
lessons
learned
from
first-in-human
CAR-T
cell,
DNA
dendritic
cell
targeting
glioblastoma.
Going
forward,
roadmap
is
provided
transformative
advance
immunotherapy,
particular
focus
opportunities
challenges
current
landscape
glioblastoma
immunotherapy
gene
therapy
reviewed
an
eye
combinatorial
approaches
harnessing
RNA
science.
Preliminary
preclinical
clinical
data
supports
concept
that
could
be
viable,
novel
approach
prolong
survival
patients
Язык: Английский